The Unique Role of Fluorodeoxyglucose-PET in Radioembolization

PET Clin. 2019 Oct;14(4):447-457. doi: 10.1016/j.cpet.2019.06.002. Epub 2019 Jul 31.

Abstract

Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.

Keywords: Dose–response; FDG-PET; Metabolic response assessment; Radioembolization.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Brachytherapy / methods*
  • Carcinoma, Hepatocellular / diagnostic imaging
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / radiotherapy
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / radiotherapy*
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography / methods*
  • Prognosis
  • Radiotherapy Dosage
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Yttrium Radioisotopes
  • Fluorodeoxyglucose F18